PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

Donald Trump's renewed push to take control of Greenland is setting off a high-stakes showdown with Denmark, a small country ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

President Trump’s proposed tariffs on Denmark could have costly consequences for Americans relying on GLP-1 medications like ...

Donald Trump has on several occasions floated the idea of buying Greenland, the autonomous Danish territory. However, there ...

Bagsværd, Denmark, 17 January 2025 – Novo Nordisk ... STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo ...

Jakob Grauslund, D.M.Sci., Ph.D., M.D., from Odense University Hospital in Denmark, and colleagues prospectively evaluated the use of semaglutide and risk for NAION in people with type 2 diabetes.

Denmark, on the island of Zealand. This biotech metropolis produces a range of active pharmaceutical ingredients, or APIs, from living cells, including insulin and semaglutide. “Look for Dubai ...

President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland could disrupt one export that is wildly popular in America: Ozempic.

With demand for those drugs skyrocketing, Novo Nordisk has been expanding production in the U.S. But the active ingredient, semaglutide, is made in Denmark. If Denmark ordered Novo Nordisk to stop ...

Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial ...